PharmaFocus Today – Page 44 – media

RiboBio’s ApoC3-Targeting siRNA Drug RBD5044 Granted Implicit Approval for Phase II Clinical Trials in China

Suzhou RiboLife Sciences Co., Ltd. (RiboLife Sciences, Hong Kong Stock Exchange: 06938) announced that RBD5044, a novel siRNA drug targeting ApoC3 independently developed by the Company, received Implicit Approval for Phase II Clinical Trials from the National Medical Products Administration (NMPA) on January 22, 2026. RBD5044 is a small nucleic acid drug for the treatment of hypertriglyceridemia developed based on the RiboGalSTAR™ liver‑targeting technology platform, and is also the second ApoC3‑targeting siRNA globally to enter clinical development. Available Phase I clinical data show that a single administration achieved significant inhibition of apolipoprotein C3 (ApoC3) by up to 84%, accompanied by a reduction in triglyceride (TG) levels of up to 70%. Furthermore, during the 6‑month follow‑up period, subjects’ TG levels remained stably below 50% of baseline, and overall lipid profiles were comprehensively improved. Meanwhile, RBD5044 demonstrated favorable tolerability, with no dose‑dependent adverse events or elevated liver enzymes observed even at ...
- Source: drugdu
- 219
- January 23, 2026
A new generation of ophthalmic dual antibodies challenges Roche’s dominant position.

Ollin recently released early data on its VEGF/Ang2 bispecific antibody OLN324 against Roche’s blockbuster product Vabysmo. The results showed that nearly 90% of patients with diabetic macular edema (DME) achieved lesion resolution within 12 weeks , while Roche’s Vabysmo only achieved 57% in the same metric. This means that the drug has the potential to cause lesion reversal and revolutionize the treatment of retinal diseases. 01 Head-to-head challenge against Roche’s pharmaceutical giant head-to-head phase 1b clinical trial conducted in multiple centers in the United States . It enrolled more than 160 patients with wet age-related macular degeneration (wAMD) or diabetic macular edema (DME) and compared the efficacy and safety of IBI324 with Vabysmo (faricimab). Results showed that at week 12, nearly 90% of patients with DME treated with OLN324 4 mg achieved DME elimination (defined as central retinal thickness CST < 325 μm), compared to 57% in the faricimab group ...
- Source: drugdu
- 238
- January 23, 2026
Leading CRO company sees net profit surge 1468%

Today (January 21), Joinn Laboratories, a leading preclinical CRO, released its 2025 annual performance forecast, projecting a net profit excluding non-recurring items of 250-370 million yuan, representing a year-on-year increase of approximately 945%-1468% . The performance curve of Joinn Laboratories has been nothing short of dramatic. In 2022, the company reached a historical peak with a net profit of 1.074 billion yuan, but then its fortunes plummeted in the following two years —net profit halved to 397 million yuan in 2023, and then plunged 81% to 74.08 million yuan in 2024. The turning point came in 2025, when the company’s net profit attributable to the parent company reached 80.71 million yuan in the first three quarters, achieving a turnaround from loss to profit compared to the same period last year . It is worth noting that Zhaoyan New Drug’s operating revenue will continue to decline in 2025, with an estimated ...
- Source: drugdu
- 177
- January 23, 2026
Robotic diagnosis and treatment is reaching a turning point towards widespread adoption.

In today’s rapidly developing technological landscape, robots are integrating into the field of surgical diagnosis and treatment at an unprecedented pace, bringing patients a more precise and safer medical experience and providing doctors with stronger technical support. However, the lack of unified standards for the pricing mechanisms of innovative medical services has, to some extent, affected their clinical promotion and sustainable development. On December 5, 2025, the National Healthcare Security Administration issued the “Guidelines for the Establishment of Pricing Items for Surgical and Treatment Assistance Medical Services (Draft for Comments)” to provincial healthcare security bureaus for internal feedback within the healthcare security system. This marks the first time that the pricing mechanisms for innovative medical services such as surgical robots have been systematically standardized at the national level. Robotic diagnosis and treatment has become a powerful tool for solving clinical pain points. “Early diagnosis of lung cancer has always been ...
- Source: drugdu
- 175
- January 23, 2026
The Phase 1 clinical trial showed amazing results, causing the stock price to surge by 166%.

Corvus Pharmaceuticals recently released updated Phase 1 clinical data on the ITK inhibitor Soquelitinib for the treatment of atopic dermatitis. Corvus Pharmaceuticals’ stock price surged 166% that day , reaching a market capitalization of $1.6 billion. Soquelitinib blocks the TCR pathway, increasing Th1 while downregulating Th2 and Th17, the latter two playing important roles in autoimmune diseases. Soquelitinib is a selective ITK inhibitor and the world’s first ITK inhibitor, with potential indications being explored for PTCL, AD, and other indications. Atopic dermatitis still presents significant unmet clinical needs, with 50% of patients failing biologic therapy. Soquelitinib has updated the data from Phase 1 cohort 4 of its clinical trial, with the clinical protocol design as follows. The patient’s baseline information is as follows. The previously released efficacy data for cohorts 1-3 after 4 weeks of treatment are as follows. In cohort 3, treatment was discontinued after 4 weeks, and the ...
- Source: drugdu
- 201
- January 23, 2026
Wanshuan® (aniline profen injection) is Yiling Wanzhou’s first approved patented new chemical drug.

Announcement from Shijiazhuang Yiling Pharmaceutical Co., Ltd. Regarding the Obtaining of Drug Registration Certificate for Aniline Profen Injection by its Wholly-Owned Subsidiary The Company and all members of its Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions. Recently, Yiling Wanzhou International Pharmaceutical Co., Ltd. (hereinafter referred to as ” Yiling Wanzhou ” ) , a wholly-owned subsidiary of Shijiazhuang Yiling Pharmaceutical Co., Ltd. (hereinafter referred to as “the Company”), received approval from the National Medical Products Administration (NMPA) for its application for marketing authorization of anilineprofen injection submitted to the Center for Drug Evaluation of the NMPA, and obtained a drug registration certificate. The relevant information is hereby announced as follows: I. Basic Information about the Drugs Certificate Number : 2026S0076 Generic name of the drug: Anilineprofen Injection Product Name: Wan Shu An ...
- Source: drugdu
- 149
- January 23, 2026
AbbVie’s “10 Billion Dollar Molecule” Receives Approval for New Indication in China

On January 22, AbbVie announced that risankizumab (trade name: Xikaiyue) has been approved in China for its second indication: the treatment of adult patients with moderate to severe active ulcerative colitis (UC) who have an inadequate, unresponsive, or intolerant attitude to conventional or biologic therapies. Risenzilumab is an IL-23 inhibitor that selectively blocks IL-23 by binding to the IL-23p19 subunit. IL-23 is a cytokine involved in the inflammatory process and is believed to be associated with many chronic immune-mediated diseases. On March 10, 2025, Risenzilumab was first approved for marketing in China for the treatment of adult patients with moderate to severe active Crohn’s disease who have an inadequate response, loss of response, or intolerance to conventional or biologic therapies.This approval for the new indication is based on the positive results of the INSPIRE and COMMAND Phase III clinical trials.The results showed that in the INSPIRE induction therapy trial, levosizumab ...
- Source: drugdu
- 247
- January 23, 2026
Verizon®, a PD-L1/4-1BB bispecific antibody, has received orphan drug designation in the European Union, potentially accelerating access to first-in-class therapy for patients worldwide.

On January 22, 2026, Nanjing Veolizhibo Biotechnology Co., Ltd. (hereinafter referred to as “Velizhibo” or the “Company”, stock code: 9887.HK) announced that its core product, Verizon® ( LBL-024, anti-PD-L1/4-1BB bispecific antibody), has been granted Orphan Drug Designation (ODD) by the European Commission (EC) for the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC). This is another important milestone in the global development of Verizon®. Currently , Verizon® has demonstrated first-in-class (FIC) or best-in-class (BIC) potential in Phase II or registrational clinical trials for three indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EP-NEC . According to the EC definition, an orphan drug is a medicine used to diagnose, prevent, or treat a life-threatening or chronically debilitating disease, and the number of patients is no more than five per ten thousand of the total EU population. Obtaining orphan drug designation provides several key incentives, including but not limited to: ...
- Source: drugdu
- 151
- January 23, 2026
Recombinant Zoster Vaccine (Shingles Vaccine) Receives Clinical Trial Approval Notice

On the evening of January 21, 2026, Hualan Vaccine announced that it recently received the “Clinical Trial Approval Notice” issued by the National Medical Products Administration (NMPA) for its Recombinant Zoster Vaccine (CHO Cell). Following a review conducted under the Drug Administration Law of the People’s Republic of China, the Vaccine Administration Law of the People’s Republic of China, and other relevant regulations, the vaccine (accepted on October 30, 2025) has met the requirements for drug registration. Clinical trials for the prevention of herpes zoster (shingles) are now authorized to proceed. The announcement explains that Herpes Zoster (Shingles) is an acute cutaneous and neurological disease caused by the reactivation of the varicella-zoster virus (VZV) after years of dormancy. It primarily affects adults and the elderly with declining immune function. Characterized by clusters of vesicles along nerves and significant pain, it can severely impact quality of life. Its primary complication, postherpetic ...
- Source: drugdu
- 196
- January 22, 2026
HeartCare Medical (06609.HK) Announces NMPA Acceptance of Registration Application for Self-Expanding Intracranial Drug-Eluting Stent

On January 20, 2026, HeartCare Medical-B (06609.HK) issued an announcement stating that the registration application for its self-developed self-expanding intracranial drug-eluting stent has been formally accepted by the National Medical Products Administration (NMPA) of the People’s Republic of China. Designed for the treatment of intracranial atherosclerotic stenosis, the stent is capable of supporting and reopening narrowed or obstructed lumens while effectively preventing in-stent restenosis. The company stated that there are currently no similar products approved for marketing worldwide, and its research and development progress remains at a leading level within the industry. However, the announcement also noted that there is no guarantee the stent will ultimately be successfully commercialized. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares. https://finance.eastmoney.com/a/202601213625547124.html
- Source: drugdu
- 137
- January 22, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.